Should we tolerate tolerability as an objective in early drug development?
Open accessThe DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
In 1803, Friedrich Wilhelm Adam Sertürner started research on the isolation of active analgesic substances from opium. After painstaking chemical isolation he obtained crystals of an apparently pure substance. He put them into food for the mice in his cellar and for unwanted dogs in the neighbourhood; the crystals put them to sleep and killed them. Undaunted, he decided to test the drug in humans (on himself and three 17-year-old friends) ‘because experiments on animals do not give exact results’[1]. He started with what he considered to be a very low dose, but of course Sertürner only knew plant substances as medicines. They first took half a grain (30 mg) of morphine in solution, which produced flushing. After half an hour they took another 30 mg and after 15 minutes another similar dose. They developed abdominal pain and faintness and Sertürner became very sleepy. Concerned by these symptoms, he induced vomiting in all of the subjects and they eventually recovered, although one of them was quite ill and ‘spent the night in a deep sleep’. These experiments demonstrated the enormous potency of pure chemical substances on physiological functions and led to the subsequent isolation of other alkaloids (such as atropine, colchicine, codeine, and strychnine), many of which are still used in therapy today. This finding was also the start of a new discipline for studying these substances and their effects, and the first departments of pharmacology were started in Strasbourg, Edinburgh, and London. This experiment was performed many years ago, but has an uncanny resemblance to a more recent event in clinical pharmacology, in which the starting dose was chosen erroneously [2, 3]. In 1944 another fascinating experiment was performed to study the tolerability of pure d-tubocurarine. Frederick Prescott, director of clinical research at the Wellcome Research Laboratories, where the substance was isolated, decided to do an experiment on himself. He was used to doing dangerous self-experiments, and had previously injected himself with a combination of metamphetamine and morphine to see if it could be used for maintenance of blood pressure during surgery. His systolic pressure rose to 250 mmHg and he was hospitalized (he had done the experiment at home). The curare experiment was performed more carefully, with a full protocol, in the Westminster Hospital and was run by the anaesthetist Geoffrey S.W. Organe, with monitoring of blood pressure, pulse, and respiration (on a drum recorder of course). The aim was to determine the dose and to see if the drug had any analgesic properties. The ascending dose protocol started with 10 mg, after which Prescott experienced muscle weakness for about 15 minutes. A week later he was given 15 mg; the weakness was greater, but he could still swallow and cough. The dose was then increased to 30 mg, which resulted in a terrifying experience. He had respiratory paralysis when conscious, but did not have the means to communicate his distress, as he was unable to speak. The investigators went on collecting data, but Prescott started to choke on saliva and mucus. Strips of adhesive plaster were put on his legs and ripped off as a test of the analgesic properties of curare, causing him pain. He was saved by an injection of neostigmine, but the investigators never realized that he had been in extreme terror. Even so, he agreed to proceed to the last stage of the experiment, in which he received half the dose intravenously and half intramuscularly [4]. Incidentally, these stories about self experimentation come from a book by Lawrence Altman, which is essential reading for anyone involved in human experimentation. Both finding the starting dose of a new drug and its tolerability clearly have a venerable history. The question is whether this tradition should continue unchanged. The guidelines for clinical trials [5] give tolerability as an objective in early (‘Phase I’) human pharmacology trials, but there is no indication that determining this is the only or even the most important objective. Pharmacokinetics, pharmacodynamics, and even obtaining an indication of clinical effectiveness are all listed. One wonders why many, if not all, of the protocols for earlydrug studies in humans have just tolerability as the primary objective rather than some of the other objectives. Firstly, the tolerability of new medicines in single doses is not always predictive of tolerability in the clinic. For instance, rofecoxib [6, 7], tolcapone [8, 9], cerivastatin [10, 11], and ximelagatran [12, 13] all have descriptions of excellent tolerability in their early development but all were taken off the market because of serious toxicity, discovered later. This is of course neither new nor unexpected. The useful DoTS classification of adverse effects that was proposed in 2003 by Aronson and Ferner [14] may help. Adverse reactions determining tolerability may occur at doses or plasma concentrations that are too high (dire
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Establishing risk of human experimentation with drugs: lessons from TGN1412
Kenter, M., & Cohen, A. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69562-7 · Cited by 153
Self-citation
Cited by
Implications of the BIA‐102474‐101 study for review of first‐into‐human clinical trials
Eddleston, M., Cohen, A. F., & Webb, D. J. (2016) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12920 · Cited by 66
Self-citationThe Use of Biomarkers in Human Pharmacology (Phase I) Studies
Cohen, A. F., Burggraaf, J., van Gerven, J. M. A., Moerland, M., & Groeneveld, G. J. (2015) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-011613-135918 · Cited by 55
Self-citationKenter, M. J. H., & Cohen, A. F. (2015) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12605 · Cited by 17
Self-citationStructured Risk Assessment for First-in-Human Studies
van Iersel, M. T., Greenberg, H. E., & Westrick, M. L. (2017) · Therapeutic Innovation & Regulatory Science · doi:10.1177/2168479017705156 · Cited by 7
“The question is whether this tradition should continue unchanged.(31) With an accurate prediction of exposure at which significant toxicity may occur and an accurate prediction of an efficacious exposure range, the exposure range in the FiH study can be chosen to cover the exposure at the MABEL or fraction of the NOAE…”
Background
Metadata
- Authors
- Cohen, A.
- Venue
- British Journal of Clinical Pharmacology
- Publisher
- Wiley
- Published
- 2007-08-16
- Volume
- 64
- Issue
- 3
- Pages
- 249-252
- ISSN
- 0306-5251 (ISSN-L)
- 1365-2125
- OpenAlex
- W1966065189
- Cited by
- 23
- References
- 1
- FWCI
- 2.40
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Should we tolerate tolerability as an objective in early drug development? https://app.cochat.ai/papers/10.1111/j.1365-2125.2007.03023.x
- The paper
- Cohen, A. (2007). Should we tolerate tolerability as an objective in early drug development? British Journal of Clinical Pharmacology. https://doi.org/10.1111/j.1365-2125.2007.03023.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.